Rating Change
Raymond James reiterated its Outperform rating on ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on November 06, 2026.
reiterateNASDAQ:SPRY
Raymond James Reiterates Outperform Rating on ARS Pharmaceuticals, Inc. (SPRY)
Raymond James reiterated its Outperform rating on ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on November 06, 2026.
At publication ·
What changed
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) · reiterate
- Firm
- Raymond James
- Rating
- Strong Buy to Outperform
- Price at event
- $2.70
- Market capitalization
- $1.1B
At a glance
Key takeaways
- Raymond James maintained an Outperform rating on ARS Pharmaceuticals (SPRY) on November 6, 2026, with the stock trading at $2.69 and a market cap of $1.1 billion.
Market Context
ARS Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $2.69 with a market capitalization of $1.1B.
Analyst coverage from Raymond James provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ARS Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for ARS Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 06, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Nov 06, 2026 | Raymond James | Outperform | N/A |
| Jun 25, 2026 | Leerink Partners | Outperform | N/A |
| May 28, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Sep 04, 2025 | Roth Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View SPRY Stock Page
Frequently Asked Questions
What does the Outperform rating mean for SPRY?
A rating of Outperform from Raymond James reflects the analyst's outlook on ARS Pharmaceuticals, Inc. (NASDAQ:SPRY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the SPRY forecast page.